CalciMedica reports 2025 net loss $29.6M; cash $13M; KOURAGE safety review finds no drug toxicity

CalciMedica, Inc.

Net loss $29.6M ($1.97/share) vs $13.7M ($1.22/share) in 2024; R&D expense $15.2M, G&A $7.9M.
Cash, equivalents & short-term investments $13.0M as of Dec 31, 2025; expected to fund operations into Q4 2026.
KOURAGE trial in AKI discontinued; internal & external safety review found no evidence of drug-related toxicity.
Pivotal program design for Auxora in acute pancreatitis expected 1H 2026 following constructive FDA engagement.
CM5480 for PAH: IND submission anticipated in 2027; preclinical data published in JCI Insight.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.